Ubrogepant
Back to searchMolecule Structure
Scientific Name
Ubrogepant
Description of the Drug
Ubrogepant is an oral CGRP antagonist used in the acute treatment of migraine with or without aura.
Source: DrugBank Online – DrugBank.com. Retrieved 2023-03-10 from
http://www.drugbank.ca/drugs/DB15328
http://www.drugbank.ca/drugs/DB15328
Brand Name(s)
Ubrelvy
Company Owner(s)
Allergan Sales Llc
Mechanism(s) Of Action
| Target Name | Target Type | Action Type | Target ChEMBL ID |
|---|---|---|---|
| Calcitonin gene-related peptide type 1 receptor | SINGLE PROTEIN | ANTAGONIST | CHEMBL3798 |
Clinical Trial(s)
Unichem Links
| SureChEMBL | SCHEMBL3698428 | |
| Human Metabolome Database | HMDB0304882 | |
| DrugBank | DB15328 | |
| PubChem | 68748835 | |
| BindingDB | 361594 | |
| EPA CompTox Dashboard | DTXSID00160178 | |
| DrugCentral | 5361 | |
| ChemicalBook | CB62708849 | |
| Guide to Pharmacology | 10176 | |
| rxnorm | UBRELVY | UBROGEPANT |
| ZINC | ZINC000095598454 |
